FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

Steven P. Angus(University of North Carolina at Chapel Hill), Gary L. Johnson(University of Colorado Hospital), Noah Sciaky(University of North Carolina at Chapel Hill), José F. Olivares-Quintero(University of North Carolina at Chapel Hill), H. Shelton Earp(University of North Carolina at Chapel Hill), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Alastair M. Thompson(Baylor College of Medicine), Stuart R. Jefferys(University of North Carolina at Chapel Hill), Michael L. Gatza(Rutgers, The State University of New Jersey), Ian E. Krop(Yale Cancer Center), Patricia A. Spears(University of North Carolina at Chapel Hill), Timothy J. Stuhlmiller(University of North Carolina at Chapel Hill), Maki Tanioka(University of North Carolina at Chapel Hill), Lisa A. Carey(University of North Carolina at Chapel Hill), Joel S. Parker(University of North Carolina at Chapel Hill), Xiaping He(University of North Carolina at Chapel Hill), Charles M. Perou(University of North Carolina at Chapel Hill), Naim U. Rashid(Dana-Farber Cancer Institute), Gaurav Mehta(AbbVie (United States)), Xin Chen(Qingdao University), Michael P. East(Emory University), Darshan Singh(Graphic Era University), Daniel R. Goulet(University of North Carolina at Chapel Hill), Jon S. Zawistowski(Cellerant Therapeutics (United States)), Matthew G. Soloway(University of North Carolina at Chapel Hill), Lynn Chollet‐Hinton(University of North Carolina at Chapel Hill), Kristalyn K. Gallagher(University of North Carolina at Chapel Hill), Samantha M. Bevill(Broad Institute), Cheng Fan(University of North Carolina at Chapel Hill), Andres Forero‐Torres(Kirklin Clinic)
npj Breast Cancer
May 12, 2021
Cited by 24


Related Papers